Pasi A. Janne, MD, PhD

Publications

• Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA.Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or l
  22547605
• Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.Imaging of lung cancer in the era of molecular medicine.Acad Radiol. 2011 Apr;18(4):424-36.
  21277232
• Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Jänne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE.A new device for rapid isolation by size and characterization of rare circulating tumor cells.Anticancer Res. 2011 Feb;31(2):
  21378321
• Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH.Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Soli
  21220471
• Li J, Jänne PA, Makrigiorgos GM.Biotinylated Probe Isolation of Targeted Gene Region Improves Detection of T790M Epidermal Growth Factor Receptor Mutation via Peptide Nucleic Acid-Enriched Real-Time PCR.Clin Chem. 2011 Feb 16.
  21325655
• Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA.Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Cancer Res. 2011 Feb 1;71(3):1081-91.
  21266357
• Zhou W, Ercan D, Jänne PA, Gray NS.Discovery of selective irreversible inhibitors for EGFR-T790M.Bioorg Med Chem Lett. 2011 Jan 15;21(2):638-43.
  21208802
• Ortiz TM, Cohen DW, Kent MS, Jänne PA, Costa DB.KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.J Thorac Oncol. 2011 Jan;6(1):220-2.
  21178719
• Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-trans
  21030459
• Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Acad Radiol. 2011 Jan;
  21036632
• Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in M
  20952506
• Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.Activity of IPI-504, a Novel Heat-Shock Protein
  20940188
• Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory
  20979472
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J
  20979469
• Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived H
  20716641
• Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL.A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.J Thorac Oncol. 2010 Oct;5(10):1655-61.
  20736856
• Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, .Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leuke
  20686428
• Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and imp
  20729419
• Sasaki T, Rodig SJ, Chirieac LR, Jänne PA.The biology and treatment of EML4-ALK non-small cell lung cancer.Eur J Cancer. 2010 Jul;46(10):1773-80. Review.
  20418096
• Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray N, Griffin JD.Discovery of a small
  20299508
• Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin
  20472851
• Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE.Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
  20461092
• Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.Oncogene. 2010 Apr 22;29(
  20118985
• Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, Camposano S, Thiele E, Franz D, Kwiatkowski DJ.Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex.Hum Genet. 2010 Mar;127(5):573-82.
  20165957
• Cichowski K, Jänne PA.Drug discovery: inhibitors that activate.Nature. 2010 Mar 18;464(7287):358-9.
  20237552
• Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistoc
  20179225
• Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer
  19804422
• Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Lo
  20164920
• Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clon
  20129249
• Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;2
  19949011
• Cortot AB, Jänne PA.Histology... For want of anything better?.Oncology (Huntingt). 2009 Nov 30;23(13):1140-1.
  20043462
• Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature. 2009 Dec 24;462(7276):1070-4.
  20033049
• Hammerman PS, Jänne PA, Johnson BE.Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Clin Cancer Res. 2009 Dec 15;15(24):7502-7509.
  20008850
• Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-sm
  19826035
• Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-sm
• Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM.Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.Cancer. 2009 Sep 1
  19551884
• Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ.Integration of molecular profiling into the lung cancer clinic.Clin Cancer Res. 2009 Sep 1;15(17):5317-22.
  19706816
• Jänne PA, Gray N, Settleman J.Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.Nat Rev Drug Discov. 2009 Sep;8(9):709-23. Review.
  19629074
• Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western
  19671850
• Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients:
  19671843
• Mukohara T,Shimada H,Ogasawara N,Wanikawa R,Shimomura M,Nakatsura T,Ishii G,Park JO,Janne PA,Saijo N,Minami H.Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the leve
  19345478
• Park S,Holmes-Tisch AJ,Cho EY,Shim YM,Kim J,Kim HS,Lee J,Park YH,Ahn JS,Park K,Janne PA,Ahn MJ.Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell
  19487967
• Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV.Combined vascular endothelial growth factor receptor and epidermal gr
  19447865
• Kuang Y,Rogers A,Yeap BY,Wang L,Makrigiorgos M,Vetrand K,Thiede S,Distel RJ,Janne PA.Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.Clin Cancer Res. 2009 Apr 15;15(8):2630-6.
  19351754
• Smouse JH,Cibas ES,Janne PA,Joshi VA,Zou KH,Lindeman NI.EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.Cancer Cytopathol. 2009 Feb 25;117(1):67-72.
  19347832
• Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,Shapiro GI,Janne PA,Eder JP,Naughton MJ,Ellis MJ,Jones SF,Mekhail T,Zacharchuk C,Vermette J,Abbas R,Quinn S,Powell C,Burris HA.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor
  19318484
• Li J,Wang L,Janne PA,Makrigiorgos GM.Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.Clin Chem. 2009 Apr;55(4):748-56.
  19233916
• Okabe T,Okamoto I,Tsukioka S,Uchida J,Hatashita E,Yamada Y,Yoshida T,Nishio K,Fukuoka M,Janne PA,Nakagawa K.Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines
  19188161
• Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
  18980991
• Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(2
  18981003
• Janne PA.Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?.Am J Respir Crit Care Med. 2008 Oct 15;178(8):783-5.
  18832554
• Toschi L,Janne PA.Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.Clin Cancer Res. 2008 Oct 1;14(19):5941-6. Review.
  18829470
• Cioffredi LA,Janne PA,Jackman DM.Treatment of peritoneal mesothelioma in pediatric patients.Pediatr Blood Cancer. 2009 Jan;52(1):127-9.
  18819151
• Simon GR,Verschraegen CF,Janne PA,Langer CJ,Dowlati A,Gadgeel SM,Kelly K,Kalemkerian GP,Traynor AM,Peng G,Gill J,Obasaju CK,Kindler HL.Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phas
  18640937
• Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasia
  18594528
• Koivunen JP,Mermel C,Zejnullahu K,Murphy C,Lifshits E,Holmes AJ,Choi HG,Kim J,Chiang D,Thomas R,Lee J,Richards WG,Sugarbaker DJ,Ducko C,Lindeman N,Marcoux JP,Engelman JA,Gray NS,Lee C,Meyerson M,Janne PA.EML4-ALK fusion gene and efficacy of an ALK kinase
  18594010
• Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement
  18520291
• Ahn MJ,Park BB,Ahn JS,Kim SW,Kim HT,Lee JS,Kang JH,Cho JY,Song HS,Park SH,Sohn CH,Shin SW,Choi JH,Ki CS,Park CK,Holmes AJ,Janne PA,Park K.Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer
  18559606
• Janne PA.Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. Review.
  18513582
• Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Adv
  18458038
• Engelman JA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Clin Cancer Res. 2008 May 15;14(10):2895-9. Review.
  18483355
• Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.EGFR FISH assay predicts for response to cetuximab in chemoth
  17974556
• Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.J Clin Oncol. 2008 Mar 20;26(9):1465-71.
  18349397
• Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.PF00299804, an irreversible pan-ERBB inhibitor, is
  18089823
• Toschi L, Cappuzzo F, Jänne PA.Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.Ann Oncol. 2007 Jul;18 Suppl 9:ix150-5. Review.
  17631569
• Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA.Ras pathway activation in malignant mesothelioma.J Thorac Oncol. 2007 Sep;2(9):789-95.
  17805054
• Jänne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD.Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advan
  17761977
• Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jänne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH.Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.Int J Radiat Oncol Biol P
  17674974
• Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC
  17676035
• Johnson BE, Jackman D, Jänne PA.Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31. Review.
  17671154
• Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD.Fulminant hepatic failure secondary to erlotinib.Clin Gastroenterol Hepatol. 2007 Aug;5(8):917-20.
  17625975
• Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial an
  17613438
• Li J, Berbeco R, Distel RJ, Jänne PA, Wang L, Makrigiorgos GM.s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.Nucleic Acids Res. 2007;35(12):e84.
  17545195
• Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M.Prospective study of gefitinib in epidermal growth factor recept
  17538169
• Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK.Mutations in BRAF and KRAS converge on activation of the
  17510423
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.MET Amplification Leads to Gefitinib Resistance in Lu
  17463250
• Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK,.Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access
  17409909
• Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist. 2007 Jan
  17285735
• Jackman DM, Jänne PA.Does erlotinib improve symptoms in patients with lung cancer?.Nat Clin Pract Oncol. 2007 Mar;4(3):146-7.
  17262089
• Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age tre
  17228019
• Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P.Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.J Clin Oncol. 2006 Nov 20;24(33):5253-8.
  17114658
• Johnson BE, Jackman D, Jänne PA.Impact of EGFR mutations on treatment of non-small cell lung cancer.Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 7:5-9.
  17093938
• Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA,.Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expand
  17092602
• Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.Allelic dilution obscures detection of a biologically significant resistance mutatio
  16906227
• Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treat
  16983123
• Johnson BE, Jänne PA.Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer.Clin Cancer Res. 2006 Jul 15;12(14):4436s-40s. Review.
  16857824
• Jänne PA, Johnson BE.Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul
  16857820
• Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung ca
  16857812
• Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer pat
  16857818
• Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged s
  16818686
• Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Broc
  16799556
• Jänne PA.Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.J Clin Oncol. 2006 Jul 20;24(21):3319-21.
  16785470
• Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH.Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5.
  16751058
• Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase d
  16730237
• Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ.Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesotheliom
  16575008
• Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.Clin Cancer Res. 2006 F
  16467085
• Sattler M, Walz C, Crowley BJ, Lengfelder E, Jänne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD.A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.Blood. 2006 Feb 1;107(3):1237-8.
  16434495
• Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Raimes DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagri S, Hillan KJ.Mutations in the Epidermal Growth FActor
• Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA.Inhibition of the met receptor in mesothelioma.Clin Cancer Res. 2005 Nov 15;11(22):8122-30.
  16299245
• Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD.Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.Cancer Res.
  16204070
• Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants.PLoS Med. 2005 Oct 4;2(11):e313.
  16187797
• Johnson BE, Jänne PA.Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.Cancer Res. 2005 Sep 1;65(17):7525-9.
  16140912
• Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth f
  16106023
• Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK.Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesotheliom
  16098243
• Jackman DM, Chirieac LR, Jänne PA.Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.Semin Respir Crit Care Med. 2005 Jun;26(3):342-52.
  16052436
• Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.Mutations in the epidermal growth facto
  16043828
• Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M.Homozygous deletions and chromosome amplifica
  15994928
• Jänne PA, Engelman JA, Johnson BE.Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.J Clin Oncol. 2005 May 10;23(14):3227-34.
  15886310
• Mamon HJ, Yeap BY, Jänne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R.High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surge
  15735128
• Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A. 2005 Mar 8;102
  15731348
• Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med. 2005 Feb 24;352(8):786-92.
  15728811
• Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-res
  15625379
• Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.Cancer Res. 2004 Oct 15;64(20):7241-4.
  15492241
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Ther
  15118125
• Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M.An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays.Cancer Res
  15126342
• Johnson BE, Jänne PA.Basic treatment considerations using chemotherapy for patients with small cell lung cancer.Hematol Oncol Clin North Am. 2004 Apr;18(2):309-22.
  15094173
• Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE.Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.Lung Cancer. 2
  15084387
• Wirth LJ, Carter MR, Jänne PA, Johnson BE.Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.Lung Cancer. 2004 May;44(2):213-20.
  15084386
• Jänne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M.High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines.Oncogene. 2004 Apr 8;23(15):27
  15048096
• Jänne PA, Skarin AT.Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer.Clin Lung Cancer. 2002 May;3 Suppl 2:S37-41.
  14720346
• Means-Markwell M, Linnoila RI, Williams J, Jänne PA, Kaye F, O'Neil K, Johnson BE.Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5915-21.
  14676115
• Jänne PA.The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma.Ann Med. 2003;35(7):450-7.
  14649327
• Janne PA.Chemotherapy for malignant pleural mesothelioma.Clin Lung Cancer. 2003 Sep;5(2):98-106.
  14596692
• Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT.Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiot
  12738723
• Jänne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, Johnson BE.Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Cancer. 2002 Oct 1;95(7):1528-38.
  12237922
• Jänne PA, Taffaro ML, Salgia R, Johnson BE.Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.Cancer Res. 2002 Sep 15;62(18):5242-7.
  12234991
• Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R.Gemcitabine-induced radiation recall.Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):394-400.
  12023144
• Jänne PA, Rodriguez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE.Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy.Onc
  11574771
• Jänne PA, Mayer RJ.Chemoprevention of colorectal cancer.N Engl J Med. 2000 Jun 29;342(26):1960-8.
  10874065